Company Profile
Essex Bio-Technology Limited, an investment holding company develops, manufactures, and sells biologic drugs globally. Its business is organized into Ophthalmology, Surgical, and Healthcare and Partner Services segments. The company researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration.
It offers Beifushu series, such as Beifushu eye drops, eye gel, and unit-dose eye drops to treat ocular wounds; and Tobramycin, Levofloxacin, Sodium Hyaluronate, Diquafosol Sodium, and Moxifloxacin Hydrochloride eye drops Iodized lecithin capsules, as well as healthtech e-platform-related medical services, Beifuji spray and lyophilized powder, and Beifuxin gels to treat surface wounds.
It offers Carisolv, a dental caries removal gel. Its portfolio also includes mouthwash, oral care products, portable ultraviolet phototherapy devices, PELNACTM, a collagen-based artificial dermis, SCALGENTM, a double-layered artificial dermis, bioresorbable implants for dental surgery, hydrophilic contact lens, medical devices for myopia control and prevention, eye-protection lamp, and defocus customized glasses.
The company develops SkQ1 eye drop, which is in the second phase 3 clinical trial. Its portfolio also includes Bevacizumab ophthalmic injection for wet-AMD, which is in phase 3 clinical trial, and EB11-21148P, which is in phase 2 clinical trial
New therapeutics in oncology, orthopedics, and neurology. It has license agreements with Mitotech S.A. for a clinical trial of an ophthalmic solution containing SkQ1 for dry eye disease
Shanghai Henlius Biotech Inc. to co-develop a pharmaceutical product that contains an anti-vascular endothelial growth factor as a drug substance, which is intended to treat macular degeneration. Founded in 1990, the company is headquartered in Zhuhai, China.